If investors in Marathon Patent Group Inc (NASDAQ:MARA) could summarize the journey they have been on since the start of this year, the phrase “hold onto your hats” would be more than appropriate. Last year saw the price oscillate between $1.30 and $3, never being particularly bullish or bearish, but as soon as we hit […]

Aviragen Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware As of June 30, or ever become profitable. In that event, the market price per share of our common stock could decline and you could lose a portion or all of your investment in our common stock. Aviragen Therapeutics Reports Fourth Quarter and Fiscal ... Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017. “We have made great strides, working with our Board and financial advisors, in honing in on a select number of strategic alternatives,” commented Joseph M. Patti, PhD, President and Chief Executive Officer of Aviragen … Aviragen Therapeutics Reports First Quarter ... - Vaxart, Inc.

ATLANTA, Jan. 31, 2018 — Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today issued the following statement urging stockholders to vote FOR the Company’s proposed merger with Vaxart, Inc. on the WHITE proxy card. The voting period will close at the upcoming Special Meeting of Stockholders on February 6, 2018.

Adam Finerman: Olshan Frome Wolosky If the exemptive order is not received the Fund has agreed to commence a cash tender offer for up to 30% of the fund’s outstanding shares at a price per share equal to 98% of the Fund’s per share NAV. Advised Karpus Management, Inc. in successfully reaching an agreement with The Zweig Fund, Inc. and The Zweig Total Return Fund, Inc SEC Filing | Spero Therapeutics, Inc. The Company was formed as Spero Therapeutics, LLC in December 2013 under the laws of the State of Delaware. On June 30, 2017, through a series of transactions, Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc. (formerly known as Spero OpCo, Inc.), a … The weekly wrap: Astronics, Hormel, Ingersoll-Rand The shares were valued based on the Emerson's closing stock price of $67.34 on 30 October 2017, the last full trading day prior to the announcement. Originally, Emerson offered $200 in cash per share, subject to proration whereby 50% of the total consideration would be paid in cash and the remaining 50% in common shares. Old Point Financial Marathon Patent Group Inc (NASDAQ:MARA ... - Oracle Dispatch

Price and Volume Movers. Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced that its partner Sanofi Genzyme has opted not to take on development and commercial rights of VY-AADC program for advanced Parkinson’s disease. According to Voyager, Sanofi’s decision was due to the inclusion of rights only outside of the US.

The Company was formed as Spero Therapeutics, LLC in December 2013 under the laws of the State of Delaware. On June 30, 2017, through a series of transactions, Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc. (formerly known as Spero OpCo, Inc.), a … The weekly wrap: Astronics, Hormel, Ingersoll-Rand The shares were valued based on the Emerson's closing stock price of $67.34 on 30 October 2017, the last full trading day prior to the announcement. Originally, Emerson offered $200 in cash per share, subject to proration whereby 50% of the total consideration would be paid in cash and the remaining 50% in common shares. Old Point Financial

AVIRAGEN THERAPEUTICS REPORTS THIRD QUARTER FISCAL YEAR 2017 FINANCIAL RESULTS. ATLANTA, GA – May 4, 2017 – Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended March 31, 2017, which is the third quarter of the Company's 2017 fiscal year. “We are expeditiously working with our Board and financial …

AVIRAGEN THERAPEUTICS REPORTS THIRD QUARTER FISCAL YEAR 2017 FINANCIAL RESULTS. ATLANTA, GA – May 4, 2017 – Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended March 31, 2017, which is the third quarter of the Company's 2017 fiscal year. “We are expeditiously working with our Board and financial … Aviragen Therapeutics : Board Of Directors Unanimously ... Updated Investor Presentation Filed with Securities and Exchange Commission and Posted to Aviragen Website. ATLANTA, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today reiterated its support of the pending merger with Vaxart, Inc., which was unanimously approved by the Aviragen Board of Directors. Biota Pharma (BOTA) Becomes Aviragen Therapeutics; Will ... Biota Pharmaceuticals, Inc. (Nasdaq: BOTA) announced that the Company has changed its name to Aviragen Therapeutics, Inc., (Aviragen Therapeutics), a … 10-K: AVIRAGEN THERAPEUTICS, INC. - MarketWatch (EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read this discussion

Vaxart, Inc. 10-Q Nov. 7, 2017 5:29 PM | Seeking Alpha

Aviragen Therapeutics and Vaxart Enter into Merger ... Mar 12, 2020 · In addition, investors and securityholders may obtain free copies of the documents filed with the SEC by Aviragen by directing a written …

Biotech Stock Performance Review -- Aralez Pharma, Arena ... Aug 16, 2017 · Aviragen Therapeutics Shares in Alpharetta, Georgia headquartered Aviragen Therapeutics Inc. ended the day 1.69% lower at $0.58 . A … Aviragen Adjourns Special Meeting of Stockholders to Allow ... Feb 09, 2018 · Additional information regarding the directors and executive officers of Aviragen is also included in Aviragen’s Annual Report on Forms 10-K for the year ended June 30… CAS Group Announces Glass Lewis Recommendation That ...